

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



August 12, 2026

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for three months ended June 30, 2026.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website www.apollohospitals.com.

Kindly note of the same.

Thanking You,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY

SANKARAN
ARAYANAN
MUTHU
KRISHNAN

Digitally signed by
SANKARANARAYA
NAN MUTHU
KRISHNAN
Date: 2026.08.12
20:33:51 +05'30'

IS/ISO 9001 : 2000


Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greaves Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com



Apollo Hospitals Enterprise Limited



Earnings Update Q1 FY27

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.


This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

 Financial Performance Snapshot & Business Segment wise Update	4-8
 Consolidated Financials	10
 Healthcare Services	12-21
 Diagnostics & Retail Health (AHLL)	23-25
 Digital Health & Pharmacy Distribution (Apollo HealthCo)	27-31
 Annexure	33-34




Financial Performance Snapshot Q1FY27



(in ₹ Mio)		Revenue		Growth YoY(%)	EBITDA(Post Ind AS)		Margin	Growth YoY(%)	PAT		Growth YoY(%)
Healthcare Services		35,670		↑ 22%	8,617		24.2%	↑ 20%	4,803		13.5% ↑ 25%
Apollo HealthCo	Offline PD ^	26,287		↑ 22%	1,910		7.3%	↑ 14%			
	^PD:- Pharmacy Distribution										
	Online PD^ & 24 7	3,484		↑ 13%	1 (196)		Vs (732) in Q1 FY26				
Total HealthCo		29,770		↑ 20%	1,714		5.8%	↑ 83%	1,013		3.4% ↑ 78%
AHLL		4,995		↑ 15%	590		11.8%	↑ 46%	(11)		
Consolidated		70,435		↑ 21%	10,920		15.5%	↑ 28%	5,805		8.2% ↑ 34%

¹Digital Cash loss of ₹97mio for the Quarter (excluding ESOP charges).

Largest Pan India Hospital Chain



	Hospitals	Capacity Census Beds ¹	Operational Census Beds
Overall Total	77	11,147	9,857
Owned Hospitals	48	9,642	8,352
Managed Hospitals	6	806	806
Day Surgery & Cradle (AHLL)	23	699	699

¹Capacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc. Beds include recently commissioned 5 new hospitals – Pune, Defence Colony, Gachibowli, Sonarpur and Belenus.

Healthcare Services Q1 FY27 Snapshot

171,662 In-patients ↑ 13%

₹ 186,630 Avg Revenue per IP Patient ↑ 8%

70% Occupancy | Established Units 72%

Revenue ▶ ₹ 35,670 Mio ↑ 22%

EBITDA ▶ ₹ 8,617 Mio ↑ 20%

Margin 24.2%



Out-of-Hospital care

- Outpatient Clinics
- Diagnostics
- Day Surgery centers
- Single Specialty Facilities :- Dialysis, Sugar and Dental

Organizing the unorganized

- Pathology – Organized chains represent only ~30%
- Mother and Child, Specialized Surgical Centers
- IVF Centers

Apollo Cradle and Fertility and Cloudnine to combine (subject to CCI approval) to create one of India's largest Maternity and Fertility care Platforms.

AHLL's Mother & Child and Fertility Businesses Valued at INR 1,550 Crores through Combination of Cash and 9.9% Equity Stake in the Combined Entity

AHLL Q1 FY27 Snapshot



2,691
Diagnostics
Centers



299 Clinics



172

Dialysis Centers



294

Dental Centers

Revenue

₹ 4,995 Mio ↑ 15%


EBITDA

₹ 590 Mio ↑ 46%

Margin

11.8%

Significant **opportunity to grow** the primary care and diagnostics businesses
Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer



Apollo 24|7

Unmatched Size

- **49 Mn.+** Registered Users – ~ **8 Lacs** Daily Active Users

Industry-leading Growth at scale

- Platform GMV: INR 535 Cr. in Q1FY27, growth of 23% over Q1 FY26

Full stack digital healthcare platform

- First-in-class AI enabled technologies including India's first Clinical Intelligence Engine

Offline Pharmacy Distribution


- Serving 7,440 Operating Stores as on 30th June 2026.

Apollo Telehealth*

- Provides **comprehensive remote healthcare services**.
- Offers **specialized telehealth solutions** like **24/7 Tele-Emergency** and **Tele-Consultancy**.
- Expands access to **healthcare in distant regions**, improving quality of life.
- Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs

*Division of AHEL

Health Co Q1 FY27 Snapshot



Revenue → ₹ 29,770 Mio ↑ 20%

EBITDA → ₹ 2,624 Mio ↑ 22%
(excl 24|7 operating cost & ESOP)

Margin

8.8%

- Virtual Doctor Consultation
- Online Booking : Hospitals & Diagnostics
- Online Medicine delivery
- Health Insurance
- Patient e-health records
- Condition management



Hospitals


- Apollo Children's Hospital, Chennai was recognised among the World's Best Hospitals 2026 by Newsweek and Statista and received a CII award for its quality improvement initiative in paediatric epilepsy care.
- Apollo Hospitals signed an MoU with the ePlane Company to explore electric air ambulances and medical delivery drones for India's emergency healthcare network.
- Apollo Hospitals, Chennai received the FE Healthcare Awards 2026 recognitions for Excellence in Multispecialty Care – South and Excellence in Emergency & Critical Care – South, and the IHF Award for Hospital Operational Excellence.
- Apollo Hospitals, Bangalore was recognised as India's first certified Comprehensive Chest Pain and Stroke Centre by the American Heart Association and American Stroke Association, respectively.

AHLL

- Test-menu enhancement for specialty tests including biomarkers profile for alzheimer, neuroendocrine marker, meningioma prognostic FISH panel, cysticercosis IgG ELISA, Uroplakin & ROS1 carcinoma markers, various food items across CRD allergy panel, colorectal cancer custom panel etc
- Pain management & longevity services added in 2 clinics. GLP services extended to 2 more centers
- AI-based X-ray/RVG analysis implemented across the entire dental network; pilot initiated in Bangalore with a device partner for foot-health assessment of diabetic patients

Apollo HealthCo

- **Improved Pharma Economics:** Per-order profitability sustained with higher average order value.
- **Efficient User Acquisition:** User growth remained strong despite lower marketing spend, led by omni-channel and non-metro expansion.
- **Diagnostics Scale-up:** Diagnostics business expanded with growing omni-channel contribution.
- **AI-led Consultations & Insurance Growth:** AI-driven patient triaging scaled, while insurance grew ~6x.
- **AI-led Care Navigation:** Predictive analytics enabling earlier identification and referral of advanced-care patients.
- **Unified Digital-Hospital Experience:** Apollo 24|7 developing a seamless digital-to-hospital patient journey.



Consolidated Financials

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
Q1FY27	Total Revenues	35,670	4,995	29,770	70,435
	EBITDA (Pre 24 7 Cost)	8,617	590	2,624	11,831
	margin (%)	24.2%	11.8%	8.8%	16.8%
	24/7 Operating Cost			(811)	(811)
	ESOP(Non Cash expense)			(99)	(99)
	EBITDA	8,617	590	1,714	10,920
	margin (%)	24.2%	11.8%	5.8%	15.5%
	EBIT	6,820	227	1,523	8,570
	margin (%)	19.1%	4.5%	5.1%	12.2%
	PBT	6,553	35	1,398	7,987
	margin (%)	18.4%	0.7%	4.7%	11.3%
	PAT (Reported)	4,803	(11)	1,013	5,805
Q1FY26	Total Revenues	29,351	4,351	24,718	58,421
	EBITDA (Pre 24 7 Cost)	7,179	403	2,145	9,727
	margin (%)	24.5%	9.3%	8.7%	16.6%
	24/7 Operating Cost			(963)	(963)
	ESOP(Non Cash expense)			(245)	(245)
	EBITDA	7,179	403	938	8,519
	margin (%)	24.5%	9.3%	3.8%	14.6%
	EBIT	5,610	71	692	6,373
	margin (%)	19.1%	1.6%	2.8%	10.9%
	PBT	5,345	(89)	571	5,827
	margin (%)	18.2%	-	2.3%	10.0%
	PAT (Reported)	3,840	(80)	569	4,328
YOY Growth					
Revenue		22%	15%	20%	21%
EBITDA		20%	46%	83%	28%
PAT		25%	-	78%	34%

✓ Overall Consolidated Revenue grew by 21% to ₹ 70,435 mio.


✓ EBITDA grew by 28% to ₹ 10,920 mio.

✓ Consolidated PAT grew by 34% to ₹ 5,805 mio.

	HCS	Health Co	AHLL
Gross Debt	25,771	3,313	3,359
Cash & Cash Equivalents*	23,560	341	1,061
Net Debt	2,211	2,972	2,298

*Includes investments in Liquid funds and FDs of ₹ 18,555 mio.

Consol Gross Debt	32,443
Consol Net Debt	7,481



Healthcare Services

Hospitals

₹ Mio	Q1FY27	Q1FY26	YoY
No of Hospitals	48	45	
Operating beds	8,352	8,030	4%
Occupancy	70%	65%	
IP Discharges	171,662	151,517	13%
ALOS	3.09	3.14	-2%
Avg revenue per In Patient (₹)	186,630	172,328	8%
Revenue	35,670	29,351	22%
EBITDA (Post Ind AS 116)	8,617	7,179	20%
margin (%)	24.2%	24.5%	(30) bps
EBIT	6,820	5,610	22%
margin (%)	19.1%	19.1%	1 bps
PBT	6,553	5,345	23%
PAT	4,803	3,840	25%
Margin	13.5%	13.1%	38 bps

Capital employed
(ROCE – Q1FY27)

₹ 95,858



ROCE 28.5%

* capital employed excludes CWIP of ₹ 12,052 mio toward new projects under development

- ✓ Healthcare Services Revenue grew by 22% in Q1FY27 . Overall Volume grew by 13%.
(Established Units Volume grew by 11%, price of 4% and Case mix /payor mix of 3%).
- ✓ CONGO-T :- Volume in Established units grew by 11% while revenue grew by 20% in Q1FY27.
- ✓ Average Revenue per In patient grew by **8% to ₹186,630 in Q1FY27.**
- ✓ **Commissioned 5 New Hospitals in the last two quarters.**
New Units pre – operative expenses / losses in Q1FY27 is ₹ 375 mio. EBITDA margin of established units at **25.9% in Q1FY27.**



Inpatients Revenue Mix Q1FY27



* Oncology includes Radiotherapy and Chemotherapy



Healthcare Services: Expansion Plan



Commissioned 5 new hospitals (~1,000 Census beds)

Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)	Beds Commissioned (Census)
FY26 - FY27					
Pune (Phase 1 & Phase 2)	Asset Light, Green Field	384	305	₹ 665	100
Sonarpur, Kolkata	Asset Light, Green Field	270	220	₹ 310	75
Gachibowli, Hyderabad	Asset Light, Green Field	375	300	₹ 550	123
Defence Colony, Delhi	Asset Light, Green Field	42	32	₹ 65	32
Sarjapur-1	Acquisition	180	150	₹ 300	50
Gurgaon, NCR	Green Field, Acq	469	380	₹ 1,295	
FY26 - FY27 Total		1,720	1,387	₹ 3,185	380
FY28 - FY29					
Jubilee Hills (Expansion)	Brownfield	100	80	₹ 230	
Secunderabad (Expansion)	Brownfield	100	80	₹ 70	
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 205	
Indore Oncology (Expansion), Madhya Pradesh	Brownfield	60	42	₹ 70	
FY28 - FY29 Total		400	327	₹ 575	
FY30-31					
Sarjapur-2	Greenfield	455	360	₹ 944	
OMR, Chennai	Greenfield	600	500	₹ 945	
Varanasi, U.P	Greenfield	400	300	₹ 640	
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320	
Worli, Mumbai	Greenfield	575	500	₹ 1,315	
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110	₹ 570	
Guwahati (Expansion)	Brown Field	88	82	₹ 100	
Indore, Madhya Pradesh	Green Field	200	164	₹ 350	
Dwarka, Delhi	Land lease, Green Field	600	480	₹ 1,290	
Delhi Cancer Centre & Proton	GreenField	100	100	₹ 573	
Ranchi, Jharkhand	Green Field	320	240	₹ 345	
FY30-31 Total		3,678	2,996	₹ 7,393	
Grand Total		5,798	4,710	₹ 11,152	

Of the total 1,000 Census beds, excluding Gurgaon, 380 beds have been operationalized, with the remaining 620 beds planned to be progressively activated over the next 12–18 months, in line with the phased ramp-up plan.

Total Project Cost of ~₹ 11,150 crs with Balance to be spent of ~₹7,500crs.

Current Beds
(Total Census) –
Q1FY27

9,857

Includes Owned, Managed and AHLL

+4,330

Post Expansion

~14,100

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros



Healthcare Services : Operational Snapshot



- Metros:** Chennai, Hyderabad, Bangalore, Mumbai, Kolkata and NCR
- Non Metros (includes Tier1 & Tier2 cities)**
Ahmedabad, Bhubaneswar, Lucknow, Indore, Guwahati, Madurai, Trichy, Nellore, Vizag, Kakinada, Mysore, Nashik, Pune, Bilaspur, Rourkela, Karimnagar, Karur and Karaikudi.

Q1FY27	6 Metros	Non Metros
Operating Beds	4,848	3,504
Occupancy	72%	66%
ARPP -IP^	₹ 223,493	₹ 132,339

^Avg revenue per In Patient | Incls New Hospitals

	PAN INDIA		
	Q1FY27	Q1FY26	YoY
Operating Beds	8,352	8,030	4.0%
Bed Occupancy Rate (%)	70%	65%	
Inpatient volume	171,662	151,517	13.3%
Inpatient ALOS (days)	3.09	3.14	-1.5%
Total Net Revenue (₹ mio) ⁽²⁾	38,894	32,244	20.6%
Avg revenue per In Patient	186,630	172,328	8.3%

Above includes New Hospitals
¹Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control

Established Units Occupancy	72%	65%
-----------------------------	-----	-----



Tamil Nadu Region



Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore



	Tamil Nadu Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	2,002	2,033	-1.5%
Bed Occupancy Rate (%)	70%	62%	
Inpatient volume	42,244	37,522	12.6%
Inpatient ALOS (days)	3.03	3.06	-1.1%
Total Net Revenue (₹ mio)	11,395	9,824	16.0%
Avg revenue per In Patient	213,309	202,525	5.3%

Q1FY27

Chennai

Operating
Beds

1,337

Occupancy

71%

ARPP-IP ^

237,098

Others

Operating
Beds

665

Occupancy

69%

ARPP-IP ^

155,542

Chennai

Current Beds

1,337

Total

2,002

Post Expansion

1,837

2,502

+500

Expansion Plan

Location	Nature	Total Beds	Census Beds
OMR, Chennai	Greenfield	600	500

AP, Telangana Region

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada



	AP, Telangana Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	1,415	1,290	9.7%
Bed Occupancy Rate (%)	67%	63%	
Inpatient volume	29,038	23,271	24.8%
Inpatient ALOS (days)	2.97	3.18	-6.6%
Total Net Revenue (₹ mio)	6,551	5,014	30.7%
Avg revenue per In Patient	194,605	182,518	6.6%

Q1FY27

Hyderabad

Operating Beds

912

Occupancy*

69%

ARPP-IP ^

204,374

Hyderabad includes New Unit

*Established units Occupancy at 74%

^Avg revenue per In Patient

Others

Operating Beds

503

Occupancy

63%

ARPP-IP ^

169,090

	Current Beds	Post Expansion
Hyderabad	912	1,359
Total	1,415	1,862

+447

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gachibowli, Hyderabad	Asset Light, Green Field	375	300
Jubilee Hills (Expansion)	Brownfield	100	80
Secunderabad (Expansion)	Brownfield	100	80
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110
Total		715	570

#Beds operationalized as on June 26: Gachibowli – 123 beds



	Karnataka Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	831	776	7.1%
Bed Occupancy Rate (%)	70%	69%	
Inpatient volume	18,637	16,953	9.9%
Inpatient ALOS (days)	2.82	2.87	-1.7%
Total Net Revenue (₹ mio)	4,295	3,543	21.2%
Avg revenue per In Patient	196,748	176,417	11.5%

	Current Beds	Post Expansion
Bangalore	618	1,203
Total	831	1,416

+585

Expansion Plan

Location	Nature	Total Beds	Census Beds
Malleswaram & Mysore Expansion	Brownfield	140	125
Sarjapur-1	Acquisition	180	150
Sarjapur-2	Greenfield	455	360
Total		775	635

#Beds Operationalized in Q1FY27 :- Sarjapur-1 – 50 beds

Q1FY27

Bangalore

Operating Beds

618

Occupancy

69%

ARPP-IP ^

217,182

Bangalore includes New Unit

*Established units Occupancy at 74%

^Avg revenue per In Patient

Others

Operating Beds

213

Occupancy

71%

ARPP-IP ^

135,352

Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela



	Eastern Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	1,931	1,836	5.2%
Bed Occupancy Rate (%)	76%	71%	
Inpatient volume	37,368	33,317	12.2%
Inpatient ALOS (days)	3.56	3.55	0.1%
Total Net Revenue (₹ mio)	7,343	6,109	20.2%
Avg revenue per In Patient	158,942	145,192	9.5%

	Current Beds		Post Expansion
Kolkata	811	+145	956
Total	1,931	+467	2,398

Expansion Plan

Location	Nature	Total Beds	Census Beds
Sonarpur, Kolkata	Asset Light, Green Field	270	220
Guwahati (Expansion)	Brown Field	88	82
Ranchi, Jharkhand	Green Field	320	240
Total		678	542

#Beds operationalized as on Q1FY27: Sonarpur – 75 beds

Q1FY27

Kolkata

Operating Beds

811

Occupancy*

79%

ARPP-IP ^

240,335

Kolkata includes New Unit
*Established units Occupancy at 86%

Others

Operating Beds

1,120

Occupancy


73%

ARPP-IP ^

107,807



	Western Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	940	888	5.9%
Bed Occupancy Rate (%)	58%	52%	
Inpatient volume	15,370	13,097	17.4%
Inpatient ALOS (days)	3.21	3.23	-0.5%
Total Net Revenue (₹ mio)	3,163	2,464	28.3%
Avg revenue per In Patient	173,128	157,256	10.1%



Expansion Plan

Location	Nature	Total Beds	Census Beds
Pune (Phase 1 & Phase 2)	Asset Light,Green Field	384	305
Worli, Mumbai	Greenfield	575	500
Total		959	805


Q1FY27

	Mumbai		Others
Operating Beds	392	Operating Beds	548
Occupancy	68%	Occupancy*	51%
ARPP-IP ^	212,041	ARPP-IP ^	137,383


Others includes New Unit
*Established units Occupancy at 56%

^Avg revenue per In Patient

#Beds operationalized as on Q1FY27: Pune – 100 beds



	Northern Region		
	Q1FY27	Q1FY26	YoY
Operating Beds	1,233	1,207	2.2%
Bed Occupancy Rate (%)	73%	70%	
Inpatient volume	29,005	27,357	6.0%
Inpatient ALOS (days)	2.81	2.82	-0.4%
Total Net Revenue (₹ mio)	6,146	5,290	16.2%
Avg revenue per In Patient	179,989	163,960	9.8%



Q1FY27


Delhi NCR		Others	
Operating Beds	778	Operating Beds	455
Occupancy	76%	Occupancy	66%
ARPP-IP ^	218,971	ARPP-IP ^	126,376

Delhi NCR includes New Unit
*Established units Occupancy at 79%

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gurgaon, NCR	Green Field, Acq	469	380
Varanasi, U.P	Greenfield	400	300
Lucknow (Expansion), U.P	Brownfield	200	160
Indore Oncology (Expansion), Madhya Pradesh	Brownfield	60	42
Indore, Madhya Pradesh	Green Field	200	164
Defence Colony, Delhi	Asset Light,Green Field	42	32
Dwarka, Delhi	Land lease, Green Field	600	480
Delhi Cancer Centre & Proton	GreenField	100	100
Total		2,071	1,658

#Beds operationalized as on Q1FY27: Defence Colony – 32 beds



Diagnostics & Retail Health

Apollo Health & Lifestyle Ltd



Primary Care



- ▶ Core Primary Care revenue grew ~7% YoY in Q1 FY27
- ▶ Net addition of 17 Primary Care partners & 5 Dialysis centres to the network in Q1 FY27
- ▶ Plan to launch a few owned clinics by the end of FY27

Diagnostics



- ▶ Net addition of 2 HLMs & 188 Collection Centers to the network
- ▶ Wellness segment grew by ~38% YoY in Q1 FY27 - ~20% of Diagnostics revenue
- ▶ Specialty segment grew by ~41% YoY in Q1 FY27. ~50 new specialty tests added to the portfolio in Q1

Specialty Care



- ▶ Cradle & Fertility: ~4% YoY revenue growth in Q1 FY27
- ▶ Spectra: Renovations planned for multiple centers in upcoming quarters



AHLL Financials Q1FY 27

(₹ mio)



		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
Q1FY27	Revenue	1,266	2,003	1,927	-201	4,995
	EBITDA	245	281	214	-150	590
	margin (%)	19.4%	14.0%	11.1%	-	11.8%
	EBIT	175	203	12	-162	227
	PAT	143	184	-132	-205	-11
Q1FY26	Revenue	1,135	1,524	1,883	-191	4,351
	EBITDA	197	119	240	-154	403
	margin (%)	17.4%	7.8%	12.8%	-	9.3%
	EBIT	125	52	50	-156	71
	PAT	89	45	-93	-158	-117
Growth						
	Revenue	12%	31%	2%	-	15%
	EBITDA	24%	136%	-11%	-	46%

- ✓ AHLL Revenue & EBITDA grew by 15% & 46% YoY in Q1 FY27 respectively;
 - Primarily driven by 31% & 136% YoY growth in Diagnostics Revenue & EBITDA respectively

- ✓ ~2.5x YoY growth in combined PAT of Diagnostics & Primary care in Q1 FY27



Network	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra ¹	Birthing Centers ^{1*}	Total
	299	78	294	172	2,691	23	33	3,590
Footfalls / Day	2,539	589	220	2,894	24,778	89	113	31,221
Gross ARPP	2,561	3,493	7,372	1,739	808 [#]	113,668	81,949	1,664

Includes BOMA¹

Includes IVF*

Without CRL, Diagnostics Gross ARPT is 960[#]

Diagnostics : Key Parameters




Operational footprint
(as of June 30, 2026)


~440+
Cities
presence

116
Labs

Avg. Footfalls per day & Avg. gross realization per patient (INR)*



Network Growth – Collection Centers




2,550+
Collection Centres

4,000+
Pick-up Points
(PUPs)

1. EBITDA post IND AS 116;

* Footfalls and ARPV for diagnostics represent outpatient / external business



Digital Health & Pharmacy Distribution **Apollo HealthCo**

India's Largest Omni-Channel Healthcare Platform



Apollo 247 Digital Platform



~49 Mn+ Registrations




~15,330+ Doctors

Daily Active Users ~8 Lakh

Daily Consultations ~14,600

Daily Medicine Orders ~53,000

Daily Sample Collections ~2,750+



Virtual Doctor Consultation



Online Booking : Hospitals & Diagnostics



Online Medicine delivery



Insurance




Patient e-health records



Condition management

Apollo Pharmacy Platform



7,440 Stores

Added (Q1)


151

Closed (Q1)

0

~14.6%

Omni Private label / generics mix - Q1'FY27



Apollo HealthCo Financials Q1 FY27

(₹ mio)



₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
Q1FY27	Total Revenues	26,287	3,484	29,770
	EBITDA (Pre 24 7 Cost)	1,910	714	2,624
	margin (%)	7.3%	20.5%	8.8%
	24/7 Operating Cost		(811)	(811)
	ESOP(Non Cash expense)		(99)	(99)
	EBITDA	1,910	-196	1,714
	margin (%)	7.3%	-	5.8%
	EBIT			1,523
	PBT			1,398
	PAT (Reported)			1,017
Q1FY26	Total Revenues	21,634	3,085	24,718
	EBITDA (Pre 24 7 Cost)	1,669	476	2,145
	margin (%)	7.7%	15.4%	8.7%
	24/7 Operating Cost		(963)	(963)
	ESOP(Non Cash expense)		(245)	(245)
	EBITDA	1,669	-732	938
	margin (%)	7.7%	-	3.8%
	EBIT			692
	PBT			571
	PAT (Reported)			571
Revenue		22%	13%	20%
EBITDA (Pre 24 7 Cost)		14%	50%	22%

HealthCo (Q1' FY27 vs Q1' FY26)


- Health Co Revenue growth @22% growth in Q1' FY27 vs Q1' FY26 excluding closure of non profitable corporate partner (Offline PD @ 22%, and Online PD + Apollo 247 @ 24%)
- PAT increased 78% to Rs. 1,017 Mn in Q1'FY 27, compared to Rs. 571 Mn in Q1'FY26.
- Lowest Digital cash loss of Rs 97 Mn in Q1'FY27, reduction by Rs 390 Mn Year over year
- Digital Revenue growth @ 24% excluding closure of non profitable corporate partner
- Investment in manpower cost (expanding PL & Generics team), one time expenditure in network resulted into ~0.4% reduction in offline PD margins %


Apollo Telehealth (under AHXL)

- Generated Revenue of Rs 120 Mn, with EBITDA of (Rs 230) Mn for Q1'FY27

Digital Operational Metrics :

- Platform GMV (23% YoY Growth) : Rs 5,351 Mn in Q1' FY27, over Rs. 4,364 Mn Q1' FY26 (excluding GST impact)
- Consistent source for new customer acquisition (Polygon & Omni Acquisition strategy)





Undertaking below transactions sequentially, via a scheme of arrangement

Step 1

- Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform (shares of AHEL in Apollo Healthco Ltd) & remote telehealth division of AHEL into New Co

Step 2

- Amalgamation of Apollo Healthco Ltd with and into New Co


Step 2

- Amalgamation of Keimed Private Limited with and into New Co

**Upon effectiveness of the Scheme (Post Shareholder and NCLT approval),
New Co to become an 'Indian Owned and Controlled Company' (IOCC), and apply for listing on stock exchanges**



Composite scheme: Resultant Shareholding Structure as approved by Shareholders



Estimated Listing by Q4FY27 post all approvals.

- Automatic listing of New Co
- Direct participation of AHEL shareholders in New Co

** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger/ demerger process is ~ 2.5%.


Combined Proforma Financial Metrics (Proposed New Co) Q1FY27

(₹ mio)



	Combined FY26	Combined Q4'FY26	Q1'FY27				Combined Q1'FY27
			Offline Pharma Distribution	+ Online Pharma Distribution+247	= Total Healthco	+ Keimed	=
Revenue	1,90,366	49,865	26,287	3,484	29,770	41,151	53,468
EBITDA, Pre INDAS	13,749	3,503	1,855	702	2,557	1,341	3,898
EBITDA %	7.2%	7.0%	7.1%	20.2%	8.6%	3.2%	7.3%
24/7 Operating cost	-3,488	-732	-	-811	-811	-	-811
ESOP Non Cash charge	-1,178	-227	-	-99	-99	-	-99
EBITDA, Pre IndAS	9,083	2,544	1,855	-208	1,647	1,341	2,988
EBITDA %	4.8%	5.7%	7.1%	N.M	5.5%	3.2%	5.6%
Excluding Digital	6.5%	6.3%					6.4%

Company expects to achieve INR 250 bn of run rate annualized revenue in Q4 FY27 with EBITDA a range of ~6.5% - 7.0%



Annexure




Basis of Consolidation



AHEL Standalone Hospitals (100% Ownership)	Location
Chennai Main	Chennai
ACI - Chennai	Chennai
Tondiarpet - Chennai	Chennai
FirstMed - Chennai	Chennai
Apollo Children's Hospital	Chennai
Apollo Specialty, Vanagaram	Chennai
ASH Perungudi	Chennai
Women & Child, Shafee Mohammed Road	Chennai
Apollo Proton & Cancer care	Chennai
Madurai	Madurai
Karur	Karur
Karaikudi	Karaikudi
Trichy	Trichy
Nellore	Nellore
Hyderabad	Hyderabad
Bilaspur	Bilaspur
Rourkela	Odisha
Mysore	Mysore
Vizag (old & new)	Vizag
Karim Nagar	Karim Nagar
Bhubaneswar	Bhubaneswar
Jayanagar	Bangalore
Nashik	Nashik
Malleswaram	Bangalore
Navi Mumbai	Mumbai
Pune	Pune
Defence Colony, Delhi	Delhi
Financial District	Hyderabad

Subsidiaries	Location	Description	AHEL Ownership
Material Subs			
Apollo HealthCo Limited	India	Digital Omni-Channel Healthcare services Platform	99.68%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	100.00%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	76.20%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Apollo PET-CT Pvt Ltd	Hyderabad	Diagnostics	100.00%
Apollo HealthTech	India	Digital Omni-Channel Healthcare services Platform	100.00%
Associates			
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapeutics Pvt Ltd	India	Stemcell Banking	37.75%



IND AS - 116 : Impact on P&L and Balance Sheet –Q1FY27



AHEL Standalone (post IND AS 116)



Balance sheet

Right of use Asset as of 30 June, 2026	↑ 13,661
Lease liabilities as of 30 June, 2026	↑ 13,693
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓ 2,109



Profit & Loss

Revenue	
Other expenses (Lease rent)	↓ 395
EBITDA	↑ 395
Amortisation	↑ 233
EBIT	↑ 162
Finance charge	↑ 280
PBT	↓ 118

AHEL Consolidated (post IND AS 116)



Balance sheet

Right of use Asset as of 30 June, 2026	↑ 27,923
Lease liabilities as of 30 June, 2026	↑ 28,766
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓ 3,052



Profit & Loss

Revenue	
Other expenses (Lease rent)	↓ 847
EBITDA	↑ 847
Amortisation	↑ 566
EBIT	↑ 281
Finance charge	↑ 549
PBT	↓ 267

Thank you